Evidence map›Paper›PMID 40866646›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2026

The SCARLET trial: a prospective phase II study of somatostatin receptor imaging for potential radiotheranostic application in patients with relapsing and refractory multiple myeloma.

Wendy Delbart, Ioannis Karfis, Marie Vercruyssen, Roland De Wind, Nathalie Meuleman, Zéna Wimana, Patrick Flamen, Erwin Woff

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04379817 (Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04379817 phase2completednot on this map

Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients

TypeinterventionalSponsorJules Bordet InstituteRan2020 to 2024Enrolled23ConditionsMultiple MyelomaArmsGallium-68 labelled DOTA-conjugated SSTR targeting peptide PET/CT
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wendy DelbartNuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium. wendy.delbart@hubruxelles.be.ORCID 0000-0001-6674-9493
Ioannis KarfisNuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Marie VercruyssenHematology Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Roland De WindPathology Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Nathalie MeulemanHematology Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Zéna WimanaNuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Patrick FlamenNuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Erwin WoffNuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.

Funding

Association Jules Bordet 2016-15
6 · The paper itself

Abstract

purposeThis phase II study investigates the expression of somatostatin receptors (SSTR) in relapsing and refractory multiple myeloma (rrMM) patients for potential radiotheranostic application.

methodsSeventeen triple-class exposed rrMM patients who demonstrate [

resultsAll patients had measurable disease on [

conclusionIn heavily pretreated rrMM patients showing avid disease on [

trial registrationNCT04379817, Registered on 4 May 2020, https://clinicaltrials.gov/study/NCT04379817?cond=multiple%20myeloma&term=scarlet&rank=1.

Indexed as

Multiple MyelomaPositron Emission Tomography Computed TomographyReceptors, SomatostatinAdultAgedAged, 80 and overFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedOrganometallic CompoundsProspective StudiesRadiopharmaceuticalsRecurrenceFluorodeoxyglucose F18gallium Ga 68 dotatateOrganometallic CompoundsRadiopharmaceuticalsReceptors, SomatostatinMolecular imagingMultiple myelomaRadiotheranosticsSomatostatin receptors

Identifiers

PMID40866646

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.